ILMN vs JNJ: fair value comparison
Illumina, Inc. and Johnson & Johnson · Updated 2026-09-12
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, ILMN currently sits closer to the top of our discount ranking.
| ILMN | JNJ | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $207.13 | $265.58 |
| 12-month range | $102.26–$207.13 | $185.08–$271.19 |
| Sector rank | #106 of 113 Healthcare | #108 of 113 Healthcare |
| Quality grade | C | C |
| Leverage | Moderate | Moderate |
| Margin trend | Stable | Expanding |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | — | Fairly Valued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: ILMN fair value analysis · JNJ fair value analysis